ImmuneOncia Therapeutics Inc.

ImmuneOncia Therapeutics Inc. is a biopharmaceutical company based in Korea South, established in 2016 through a joint venture between Yuhan and Sorrento. The company's focus is on immuno-oncology, with a mission to develop safe, effective, and novel immunotherapies for oncology patients globally. ImmuneOncia's portfolio includes a range of immune checkpoint antibodies, with its lead antibody IMC-001 having completed a Phase I study in Feb 2019 and progressing to a Phase 2 study. Additionally, the company is working on developing several antibodies targeting novel immune checkpoints. The recent round of investment for ImmuneOncia took place on 17 January 2022, with a significant investment of KRW24.50B. This round saw participation from a diverse group of investors including Premier Partners, E&Investment, K2 Investment Partners, Meritz Securities, Welcome Capital, BNH Investment, 한양증권(주), and Yuhan Corporation. ImmuneOncia's commitment to advancing immuno-oncology, coupled with its partnerships and recent substantial investment, positions it as a company to watch in the biotechnology and pharmaceutical industries. With its innovative approach and strong backing, ImmuneOncia is poised to play a significant role in changing the standard of cancer treatment, particularly with the potential of bringing Korea's 1st immuno-oncology drug to market.